Business Context and Reporting Period
Prelude Therapeutics Inc. (PRLD) filed a Form 8-K on November 30, 2021, reporting the entry into a material definitive agreement. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or general liquidity metrics. The only financial data disclosed relates to the new lease agreement:
- Aggregate Estimated Rent: Approximately $33.8 million over the initial term.
- Security Deposit: $4.0 million paid via letter of credit (reducible to $0.5 million over time).
- Lease Term: Initial term of 162 months with three five-year extension options.
Material Changes
The company entered into the "Chestnut Run Lease" with Crisp Partners, LLC for approximately 81,000 square feet of office and lab space at 984 Centre Road, Wilmington, Delaware. This location is intended to serve as the company's new headquarters. The commencement date is defined as the earlier of the Landlord Work Substantial Completion Date or the date the company takes possession.
Outlook and Risks
The filing indicates a strategic expansion of the company's physical footprint to consolidate operations at a new headquarters. No specific financial guidance, management commentary on future performance, or discussion of risks beyond the standard lease obligations is provided in this document.
Investor Verification Points
- Verify the exact "Commencement Date" to determine when rent obligations officially begin.
- Review the full text of the Chestnut Run Lease (to be filed as an exhibit to the 2021 Form 10-K) for details on expansion rights and termination clauses.
- Monitor the company's cash position to ensure it can sustain the $33.8 million rent obligation over the 162-month term.